Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

about

Canagliflozin-induced pancreatitis: a rare side effect of a new drug.

P2860

Q35811434-8713CF40-AB81-4C01-95CB-664A87398FA4

P2860

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q41476579

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

@en

type

Item

label

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

@en

prefLabel

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

@en

P1476

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

@en

P2093

Deborah Hinnen

http://www.w3.org/2001/XMLSchema#string

Virginia Valentine

http://www.w3.org/2001/XMLSchema#string

P2860

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

SGLT2 inhibition--a novel strategy for diabetes treatment.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Is hepatic glucose production increased in type 2 diabetes mellitus?

P304

5-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIACLIN.33.1.5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272080827

http://www.w3.org/2001/XMLSchema#string

P698

25653467

http://www.w3.org/2001/XMLSchema#string

P932

4299744

http://www.w3.org/2001/XMLSchema#string

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

about

P2860

P2860

Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932